Oncology

EGFR

CHEMBL203

ACCUMULATING

5,497 ADMET-validated compounds across 35,946 generated. Library buildup phase — Pareto rank-1 selection underway prior to CRO triage.

ADMET Passed

5,497

Pareto Rank 1

447

CRO

Accumulating

Stage

Library buildup

Mechanism

EGFR (HER1) tyrosine kinase inhibition — RTK signaling node for cell proliferation and survival

Precedent

Erlotinib, Gefitinib (1st-gen, 2003–2004) · Afatinib (2nd-gen) · Osimertinib (AstraZeneca, 3rd-gen, approved 2015) · Lazertinib (Yuhan/J&J)

Indications

NSCLC · Glioblastoma · Pancreatic cancer

Milestones

2026-W17

EGFR added as 5th target — pipeline integration complete

2026-W18

ADMET library passing 5,000 compounds — Pareto convergence beginning